Positive two year data for Cosentyx (secukinumab) from FUTURE 1 study for psoriatic arthritis- Novartis
Novartis announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, secukinumab maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.
These results from the FUTURE 1 study represent the longest secukinumab Phase III study in PsA to date. Responses in joint and skin disease, physical function and quality of life at Week 24 were maintained over two years. After two years of treatment, 67% of patients (n=202) treated with secukinumab 150 mg achieved the standard treatment goal of an ACR 20 response (American College of Rheumatology response criteria). In addition, 84% of patients showed no further progression in joint damage as shown by x-ray assessment. Secukinumab was well tolerated with a safety profile consistent with that observed in previous studies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins